FDA Accepts ANDA for Viloxazine Hydrochloride by Appco Pharma
The FDA has accepted the ANDA for Viloxazine Hydrochloride submitted by Appco Pharma.
Published: July 8, 2026
Updated: July 8, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Antidepressant
Company: Appco Pharma
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Appco Pharma
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of the ANDA for Viloxazine Hydrochloride by Appco Pharma is significant as it opens the door for new competition in the antidepressant market. Portfolio teams need to evaluate the potential impact on existing products and market dynamics.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the progress of the ANDA review and any subsequent market launch timelines.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.